Journal article
Adhiraj Roy, S. Prasad, Yuzhou Chen, Ya-Ling Chao, Yu Liu, Jinjun Zhao, Q. Wang
American Journal of Pathology, 2023
American Journal of Pathology, 2023
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Roy, A., Prasad, S., Chen, Y., Chao, Y.-L., Liu, Y., Zhao, J., & Wang, Q. (2023). Protein kinase D2 and 3 promote prostate cancer cell bone metastasis by positively regulating Runx2 in a MEK/ERK1/2-dependent manner. American Journal of Pathology.
Chicago/Turabian
Click to copy
Roy, Adhiraj, S. Prasad, Yuzhou Chen, Ya-Ling Chao, Yu Liu, Jinjun Zhao, and Q. Wang. “Protein Kinase D2 and 3 Promote Prostate Cancer Cell Bone Metastasis by Positively Regulating Runx2 in a MEK/ERK1/2-Dependent Manner.” American Journal of Pathology (2023).
MLA
Click to copy
Roy, Adhiraj, et al. “Protein Kinase D2 and 3 Promote Prostate Cancer Cell Bone Metastasis by Positively Regulating Runx2 in a MEK/ERK1/2-Dependent Manner.” American Journal of Pathology, 2023.
BibTeX Click to copy
@article{adhiraj2023a,
title = {Protein kinase D2 and 3 promote prostate cancer cell bone metastasis by positively regulating Runx2 in a MEK/ERK1/2-dependent manner.},
year = {2023},
journal = {American Journal of Pathology},
author = {Roy, Adhiraj and Prasad, S. and Chen, Yuzhou and Chao, Ya-Ling and Liu, Yu and Zhao, Jinjun and Wang, Q.}
}
Abstract
Advanced stage prostate tumors frequently metastasize to the bone, which is the main cause of death. The protein kinase D (PKD) family has been implicated in prostate cancer development; however, its role in prostate cancer metastasis has not been investigated. This study examined the contribution of PKD, particularly PKD2 and 3 (PKD2/3), to the metastatic potential of prostate cancer cells and the effect of PKD inhibition on prostate cancer bone metastasis in vivo. The data showed that depletion of PKD2/3 by siRNAs or inhibition by a PKD inhibitor CRT0066101 in AR-positive and -negative castration-resistant prostate cancer cells potently inhibited colony formation and cell migration. Furthermore, depletion or inhibition of PKD2/3 significantly blocked tumor cell invasion and suppressed the expression of genes related to bone metastasis in the highly invasive PC3-ML cells. The reduced invasive activity resulting from PKD2/3 depletion was in part mediated by the transcription factor Runx2, as its silencing decreased PKD2/3-mediated metastatic gene expression through the MEK/ERK1/2 signaling axis. Furthermore, inhibition of PKD by CRT0066101 potently decreased the frequency of bone micrometastases in a mouse model of bone metastasis based on intracardiac injection of PC3-ML cells. These results indicate that PKD2/3 play an important role in the bone metastasis of prostate cancer cells, and their inhibition may be beneficial for the treatment of advanced stages of prostate cancer.